With Regeneron’s high profile, single-person, single-site, clinical trial proving successful (along with much supporting other clinical data!), will neutralising antibodies surf the second wave? Our COVID-related blogs focus on capacity and cost of making the treatments and understanding opportunities or bottlenecks in large scale provision
General questions What is your name, company name and position? D Dr David Pollard, Head of Advanced Materials and Processing, which is one of the three pillars of the newly formed Sartorius Corporate Research. The other two pillars of corporate research
Are you interested in optimising performance of your upstream biologics manufacturing? Cell retention/media perfusion devices increase the viable cell density of bioreactors and can be used to reduce the number or volume of seeding stages of the production bioreactor (1,2,3). Additionally, the production cycle can
A Case Study based on the Covid-19 vaccine being developed by the Jenner Institute, Oxford University. An affordable, global vaccine for Covid-19 is still seen as the best chance of protecting vulnerable people and populations at the same time as getting everyone back to normal
The biopharmaceutical industry is investigating various biologics as treatments for COVID-19. This blog looks at the scale of global manufacturing that may be required and the associated cost of goods of these drug products for COVID-19. Vaccine manufacturing will be discussed in a separate blog.
Biopharmaceutical manufacturing capacity, efficiency, flexibility and economics are all important outputs for organisations to optimize and continuously review. BioSolve Process is the biopharmaceutical industry’s most powerful software for bioprocess analysis. Due to the complexity of therapeutic manufacturing there are many variables contributing to the overall
As cell therapy processes mature and advance further beyond clinical trials, the shift to the manufacture and supply of affordable therapies will become more important. These therapies are expensive. High cost of goods (COGs) can be a cause of commercial failure with cell therapies, so
As we develop new processes and evaluate new technologies it is important to consider sustainability and the environmental impact and how this can be improved. It is an area that we have been actively considering since the early days of BioSolve Process; when the focus
World-class bioprocess modelling software developer unveils new customisable features for users. LONDON, 11 December 2019 – Biopharm Services, the bioprocess analysis software developer, today announced the release of the latest version of its flagship process analysis and economic modelling tool, BioSolve Process. BioSolve Process 8
The BioSolve User forum was held in the historic town of Leiden; we welcomed over 20 attendees. We met together for a in-depth review of new features, and to learn from and interact with other users in the expanding community. A major theme of the
